.png)
The Gummy Has a Dose Problem Nobody Is Talking About
Quick answer: Gummies are the fastest growing supplement format in the industry, but most brands cite clinical evidence gathered in capsule or tablet form at doses their gummy products can't physically deliver. Changing format doesn't just change the consumer experience — it changes the dose, the stability, the bioavailability, and therefore the evidence base that legitimately supports the claim. Regulators and plaintiff attorneys are starting to notice.
The gummy vitamin market is expected to grow from USD $8.63 billion in 2025 to USD $12.08 billion by 2029, and walking through any supplement retailer in 2026 makes that trajectory feel entirely believable. Gummies have moved from novelty to category standard across beauty supplements, probiotics, vitamins, adaptogens, sleep support, and cognition products. The format continues to grow in popularity as more consumers embrace non-pill alternatives that fit their lifestyles, and the commercial logic is straightforward: better compliance, broader consumer appeal, and a format that feels like a product rather than a prescription. Bryan Johnson ProtocolFederal Trade Commission
None of that is wrong. Gummies genuinely do improve adherence for many consumers, and adherence matters to real-world supplement efficacy. The problem isn't the format. The problem is that brands are making claims about gummy products while citing evidence gathered under entirely different conditions, at entirely different doses, in an entirely different delivery system. That gap is quietly becoming one of the most significant compliance issues in the supplement category.
Why Format Matters More Than Most Brands Realise
When a brand reformulates a capsule product into a gummy, or launches a gummy version of an established supplement, the clinical evidence for the active ingredient doesn't automatically transfer. Three things change simultaneously, and each has direct implications for the claims the brand can legitimately make.
The first is dose capacity. A standard capsule can deliver 500mg to 1,000mg of an active ingredient in a single serve. A gummy has a physical limit of approximately three to five grams total weight per piece, a significant portion of which is occupied by the gummy matrix — gelatine or pectin, humectants, sweeteners, flavouring, and colouring. Some substances simply aren't viable in gummy form, and capsules can pack significantly more active ingredient into a smaller package. For ingredients where clinical evidence was gathered at doses of 500mg or above — magnesium, ashwagandha, berberine, many probiotics at specific CFU counts — a standard two-gummy serving often delivers a fraction of the studied dose. Blackswan
The second is stability. Preserving potency in gummies can be especially challenging for heat-sensitive vitamins, which tend to break down more quickly in the gummy matrix, and gummies are not designed for targeted delivery in the way capsules can be, limiting their ability to protect acid-sensitive ingredients or delay release until the product reaches the small intestine. Certain nutrients are more likely to degrade in a gummy format, and manufacturers who are not knowledgeable about which raw materials are heat-sensitive may incorporate poorly suited ingredients into the gummy matrix. The stated dose on the label may not be what reaches the bloodstream, particularly as the product ages through its shelf life. WebbutikBryan Johnson Protocol
The third is evidence population. Even where a gummy format delivers an equivalent dose to the clinical trial — which is possible with careful formulation — the study population, duration, and outcomes still need to map to the specific claim being made on the product. A vitamin D gummy study showing raised serum levels doesn't substantiate a bone health claim. A probiotic capsule trial in hospital patients doesn't substantiate an "immune support" claim for a consumer probiotic gummy.
The Litigation Signal Is Already Visible
The class action bar has been paying attention to gummy dose claims for longer than most brands realise. A class action lawsuit alleged that New Chapter misrepresented the dosage amounts of its dietary supplement gummies, with the complaint claiming that front labels on certain products led consumers to believe that each gummy contained the advertised dosage amount when multiple gummies were required to reach the stated dose. American Council on Science and Health
A separate case alleged that a supplement brand's gummy labelling departed from industry standards and common consumer expectations, with the plaintiff arguing she relied on nutrient and quantity information and paid a price premium based on what turned out to be inaccurate disclosures. Wikipedia
Trends in dietary supplement class action lawsuits increasingly target discrepancies in labelled ingredient amounts, inaccurate declarations, and labelling that fails to meet reasonable consumer expectations around dosage and nutrient content. The gummy format is particularly vulnerable because the constraints that limit dose capacity are invisible to the consumer — they're making purchasing decisions on the basis of the front label, with no way to assess whether the format can realistically deliver what the claim implies. Mito Health
The Sugar Tension Nobody Mentions in the Marketing
There's a secondary issue in the gummy format conversation that rarely surfaces in brand marketing but surfaces frequently in regulatory scrutiny. Many gummies are sweetened with refined sugar, usually two to eight grams per serving, and excess sugar consumption harms metabolism, increases blood glucose and insulin, and promotes higher body mass index. Bryan Johnson Protocol
For a product positioned as a health supplement, that creates a real tension. A "supports immune health" gummy delivering five grams of added sugar per serve is making a health claim while simultaneously delivering a dose of something most health guidance recommends limiting. For products in the metabolic health, weight management, or blood glucose support categories, the tension is more acute — and it's the kind of claim-format mismatch that regulators and plaintiff attorneys are both equipped to identify.
Gummy vitamin products often contain ingredients that do not match the label, or may have stability issues that cause a short shelf life. Well-formulated gummies from manufacturers with rigorous quality controls are genuinely effective. But the category average is considerably below that standard, and brands operating at the average are carrying risk they haven't quantified. Bryan Johnson Protocol
What Getting This Right Actually Looks Like
The gummy format is not the problem. The problem is treating a format change as a packaging decision when it's actually a formulation and evidence decision.
Before a gummy product goes to market with a specific health claim, four questions are worth answering honestly. Does the dose delivered in gummy form sit within the range used in the clinical evidence being cited? Does stability data support that the stated dose is present at end of shelf life? Does the cited evidence — its study population, duration, and primary outcomes — map to the specific claim being made on this product? And does the sugar or matrix content create any tension with the health positioning?
In Australia, the TGA's evidence requirements for listed medicines have no gummy carve-out. The evidence must support the indication for the specific product, which means the formulation, dose, and delivery system all factor into whether the substantiation holds. A permitted indication selected on the basis of capsule-form evidence, applied to a gummy at half the studied dose, is a substantiation gap that a TGA compliance review will identify.
The gummy market will keep growing. The brands that navigate it well are the ones treating each format change as an evidence question, not just a consumer experience question.
Frequently Asked Questions
Do gummy supplements have the same evidence base as capsules?Not automatically. Clinical evidence for a supplement ingredient is gathered at specific doses, in specific populations, using specific delivery systems. When a brand reformulates from capsule to gummy, the dose capacity, nutrient stability, and bioavailability can all change. The evidence base needs to be assessed for the specific gummy formulation rather than assumed to carry over from capsule-form studies.
Why can gummy supplements deliver less active ingredient than capsules?A gummy has a physical weight limit of approximately three to five grams per piece, much of which is occupied by the gummy matrix including gelatine or pectin, humectants, sweeteners, and flavouring. This leaves significantly less room for active ingredients than a capsule of comparable size. For ingredients where clinical evidence was gathered at doses of 500mg or above, a standard gummy serving may deliver a fraction of the studied dose.
Are gummy supplement claims being challenged in court?Yes. Class action lawsuits have targeted brands for misrepresenting dosage amounts on gummy supplement labels, particularly where front-of-pack labelling creates the impression that each gummy delivers the full advertised dose when multiple gummies are required. Discrepancies between labelled and actual ingredient amounts are an active area of supplement litigation in the US.
What is dose insufficiency in supplement claims?Dose insufficiency is where a supplement product delivers a dose of an active ingredient that falls below the range used in the clinical evidence cited to support its health claim. It is one of the most common grounds for class action challenges to functional and health claims on supplement products, and applies equally to gummy and non-gummy formats.
How does the TGA treat gummy supplement evidence in Australia?The TGA's evidence requirements for listed medicines apply to the specific product being listed, including its formulation, dose, and delivery system. Evidence gathered for a capsule product at a higher dose does not automatically substantiate a claim on a gummy product delivering a lower dose. The substantiation must map to the actual product being marketed.
What should brands check before launching a gummy supplement with health claims?At minimum: whether the dose delivered in the gummy format sits within the range used in clinical evidence for the claim; whether stability testing confirms the stated dose is present at end of shelf life; whether the study population and primary outcomes in cited evidence map to the specific claim being made; and whether the sugar or matrix content creates any tension with the health positioning of the product.
How Parallaxis Helps
If you're developing a gummy product and want to understand whether your evidence base holds up at the format and dose your product actually delivers, that's the kind of question we're built for. We work with supplement, nutraceutical, and functional food brands across ANZ, the US, and the EU to map evidence to claims before launch — not after a compliance review. Get in touch.